LCL161与帕比司他在骨髓瘤细胞中经非经典NF-κB和caspase-8依赖机制协同作用
研究探讨IAP拮抗剂LCL161与HDAC抑制剂帕比司他在人多发性骨髓瘤细胞中的相互作用,发现两者协同诱导凋亡,涉及非经典NF-κB通路下调及caspase-8相关外源性凋亡激活,并在原代CD138+细胞和5TGM1小鼠模型中显示活性。
要点
- LCL161与帕比司他在多种骨髓瘤细胞系(含硼替佐米耐药)中协同诱导凋亡。
- 协同致死机制涉及非经典NF-κB通路抑制和caspase-8相关外源性凋亡激活。
- 联合方案对原代骨髓瘤细胞有效,且对正常CD34+细胞无毒。
核心结论
- LCL161与LBH589在骨髓瘤细胞中通过非经典NF-κB通路失活和外源性凋亡通路激活协同诱导凋亡。
- 该方案克服多种耐药形式,对原代骨髓瘤细胞有活性,并在体内显示显著活性。
研究设计与样本
- 在人骨髓瘤细胞系(包括硼替佐米耐药PS-R)中检测LCL161与帕比司他的联合作用。
- 使用原代CD138+细胞(N=31)和CD138-/19+/20+/27+群体(N=23)及正常CD34+细胞评估毒性。
- 在免疫 competent 5TGM1小鼠骨髓瘤模型中比较联合与单药治疗的生存。
主要发现
- LCL161与帕比司他协同诱导多种骨髓瘤细胞系凋亡,包括硼替佐米耐药细胞。
- 与其他HDAC抑制剂(MS-275)或IAP拮抗剂(birinapant)也观察到类似协同作用。
- 协同致死伴随非经典NF-κB通路下调、caspase-8相关外源性凋亡激活、TRAF3上调、TRAF2和NIK下调、BCL-XL表达降低及γH2A.X诱导。
- 过表达TRAF2、NIK或BCL-XL,或shRNA敲低TRAF3,或过表达显性负性FADD,均显著降低LCL161/LBH589的致死性。
- 基质/微环境因素未能减弱LCL161/LBH589诱导的细胞死亡。
临床怎么用
- 该联合策略在骨髓瘤中显示临床前活性,尤其对硼替佐米耐药及原代骨髓瘤细胞有效。
- 联合方案对正常CD34+细胞无毒,提示治疗窗可能较宽。
局限性
- 研究主要为临床前体外和动物模型实验,尚未在临床试验中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Interactions between the inhibitor of apoptosis protein antagonist LCL161 and the histone deacetylase inhibitor panobinostat (LBH589) were examined in human multiple myeloma (MM) cells. LCL161 and panobinostat interacted synergistically to induce apoptosis in diverse MM cell lines, including those resistant to bortezomib (PS-R). Similar interactions were observed with other histone deacetylase inhibitors (MS-275) or inhibitors of apoptosis protein antagonists (birinapant). These events were associated with downregulation of the noncanonical (but not the canonical) NF-κB pathway and activation of the extrinsic, caspase-8-related apoptotic cascade. Coexposure of MM cells to LCL161/LBH589 induced TRAF3 upregulation and led to TRAF2 and NIK downregulation, diminished expression of BCL-XL, and induction of γH2A.X. Ectopic expression of TRAF2, NIK, or BCL-XL, or short hairpin RNA TRAF3 knock-down, significantly reduced LCL161/LBH589 lethality, as did ectopic expression of dominant-negative FADD. Stromal/microenvironmental factors failed to diminish LCL161/LBH589-induced cell death. The LCL161/LBH589 regimen significantly increased cell killing in primary CD138+ cells (N = 31) and was particularly effective in diminishing the primitive progenitor cell-enriched CD138-/19+/20+/27+ population (N = 23) but was nontoxic to normal CD34+ cells. Finally, combined LCL161/LBH589 treatment significantly increased survival compared with single-agent treatment in an immunocompetent 5TGM1 murine MM model. Together, these findings argue that LCL161 interacts synergistically with LBH589 in MM cells through a process involving inactivation of the noncanonical NF-κB pathway and activation of the extrinsic apoptotic pathway, upregulation of TRAF3, and downregulation of TRAF2/BCL-XL. Notably, this regimen overcomes various forms of resistance, is active against primary MM cells, and displays significant in vivo activity. This strategy warrants further consideration in MM.
引用
- Zhou L, Zhang Y, Meads MB, et al. IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB- and caspase-8-dependent mechanisms. Blood Adv. 2021. PMID: 34464977. doi:10.1182/bloodadvances.2020003597
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。